Videos

Peter O’Donnell, MD, discusses an analysis from from the KEYNOTE-045 and KEYNOTE-052 trials, showing continued efficacy and safety of pembrolizumab for patients with metastatic urothelial carcinoma after 5 years of follow-up.

Talha Munir, MD, discusses findings from an updated interim analysis of the FLAIR study at the 2022 ASH Annual Meeting & Exposition in New Orleans, LA.

Christopher R. Flowers, MD, MD Anderson Cancer Center, Houston, TX discusses the results of the GO29365 study on polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma.

At the 2022 San Antonio Breast Cancer Symposium, Rachel Jimenez, MD, reviews updates and advancements in radiotherapy technology for patients with breast cancer.

At the 2022 San Antonio Breast Cancer Symposium, Per Karlsson, MD, PhD presents results from the meta-analysis investigating the prognostic value of POLAR scores in predicting the benefit of radiotherapy for patients with breast cancer.

At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of elacestrant vs standard of care endocrine therapy for patients with ER-positive, HER2-negative, metastatic breast cancer by duration of prior...

Rachel Jimenez, MD, discusses an upcoming clinical trial examining the efficacy of advanced radiation technology in reducing radiation-related toxicity for patients with breast cancer.

Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss their approaches to biomarker testing for patients newly diagnosed with NSCLC, the role of tissue vs liquid biopsy, and how these biomarkers are used to inform treatment decisions.

Edward Garon, MD, and Lyudmila Bazhenova, MD, discuss options for frontline management of NSCLC after the most recent approval of durvalumab plus tremelimumab and chemotherapy based on results from the POSEIDON trial.

At the 2022 San Antonio Breast Cancer Symposium, Sara Hurvitz, MD, presents preliminary results from the TRIO-US B-12 TALENT trial, investigating trastuzumab deruxtecan for patients with HR-positive, HER2-low, early-stage breast cancer.